Attention A T users. To access the menus on this page please perform the following steps. 1. Please switch auto forms mode to off. 2. Hit enter to expand a main menu option (Health, Benefits, etc). 3. To enter and activate the submenu links, hit the down arrow. You will now be able to tab or arrow up or down through the submenu options to access/activate the submenu links.

Seattle-Denver Center of Innovation (COIN)

Menu
Menu
Quick Links
Veterans Crisis Line Badge
My healthevet badge
 

COIN Investigators & Staff

COIN Investigators

 

Kamal Henderson, MD
Title: Core Investigator
Assistant Professor of Medicine, University of Colorado School of Medicine
Contact: Kamal.Henderson@va.gov
Location: Denver
See Dr. Henderson's Dimensions profile that includes: publications, grants, datasets, patents and clinical trials

Return to Top

Recent Publications

Bauer KL, Haapanen KA, Demeke N, Fort MP, Henderson KH. Increasing use of systems science in cardiovascular disease prevention to understand how to address geographic health disparities in communities with a disproportionate burden of risk. Front Cardiovasc Med. 2023 Jul 13;10:1216436. doi: 10.3389/fcvm.2023.1216436. PMCID: PMC10374219. PMID: 37522076

2022

 

Henderson K, Kaufman B, Rotter JS, Stearns S, Sueta CAA, Foraker R, Ho PM, Chang PP. Socioeconomic status and modification of atherosclerotic cardiovascular disease risk prediction: epidemiological analysis using data from the atherosclerosis risk in communities study. BMJ Open. 2022 Nov 7;12(11):e058777. doi: 10.1136/bmjopen-2021-058777. PMID: 36343998

Henderson KH, Helmkamp LJ, Steiner JF, Havranek EP, Vupputuri SX, Hanratty R, Blair IV, Maertens JA, Dickinson M, Daugherty SL. Relationship Between Social Vulnerability Indicators and Trial Participant Attrition: Findings From the HYVALUE Trial. Circ Cardiovasc Qual Outcomes. 2022 Apr 14:101161CIRCOUTCOMES120007709. doi: 10.1161/CIRCOUTCOMES.120.007709. Epub ahead of print. PMID: 35418247

2021

 

Salahuddin T, Richardson V, McNeal DM, Henderson K, Hess PL, Raghavan S, Saxon DR, Valle JA, Waldo SW, Ho PM, Schwartz GG. Potential unrealized mortality benefit of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transport-2 inhibitors: A report from the Veterans Health Administration Clinical Assessment, Reporting and Tracking program. Diabetes Obes Metab. 2021 Jan;23(1):97-105. doi: 10.1111/dom.14193. Epub 2020 Oct 3. PMID: . PMID: 32902128
Learn more about this publication at Dimensions

McNeal D, Salahuddin T, Valle J, Henderson K, Richardson V, Raghavan S, Saxon D, Hess P, Ho PM, Schwartz GG. (2020). Eligibility for and use of sodium glucose cotransporter-2 inhibitors and glucagon-like peptide-1 agonists in veterans with type 2 diabetes and coronary artery disease: prospective analysis from the cardiac catheterization lab clinical assessment, reporting, and tracking (cart) program. Journal of the American College of Cardiology, Volume 75, Issue 11, Supplement 1. Page 231. ISSN 0735-1097. https://doi.org/10.1016/S0735-1097(20)30858-5
Learn more about this publication at Dimensions

Salahuddin T, McNeal D, Richardson V, Valle J, Henderson K, Raghavan S, Saxon D, Hess P, Ho PM, Schwartz GG. (2020). Potential unrealized cardiovascular benefit of novel diabetes agents in the veterans health administration system: insight from the clinical assessment, reporting, and tracking (cart) program. Journal of the American College of Cardiology. Volume 75, Issue 11, Supplement 1. Page 1836. ISSN 0735-1097. https://doi.org/10.1016/S0735-1097(20)32463-3
Learn more about this publication at Dimensions

return to top go